Skip to content
Join The Waitlist
All posts

Journey Biosciences launches NaviDKD® to predict diabetes-related kidney complications

By   ·  1 minute read
First and only scientifically-based screening technology provides an early read on the risk of developing kidney disease for people with diabetes, giving them and their doctors time to take preventive action and improve outcomes.
 

Journey Biosciences, Inc., a biotechnology company offering biomarker-based predictive risk screening technologies, today announced the launch of its flagship product—NaviDKD.

NaviDKD, a biomarker-based blood test, proactively assesses the risk of kidney disease in people with diabetes years before clinical signs or symptoms appear. Along with its proprietary Compass™ reporting platform, NaviDKD provides actionable insights for preventing and managing kidney complications before they occur.

"For the one-in-three people with diabetes who will develop kidney disease, NaviDKD provides an opportunity to change their ultimate health outcomes," said Adam Graybill, Chief Executive Officer of Journey Biosciences. "By identifying those at elevated or high risk of developing DKD before any clinical signs or symptoms, the conversation between doctors and patients can focus on taking proactive, preventive actions instead of reacting to an unwanted diagnosis."

All NaviDKD blood samples are processed in Journey Biosciences' laboratory in Cleveland, Ohio, which received CLIA certification in August 2022. 

About Journey Biosciences

Journey Biosciences is on a mission to improve the lives of people with diabetes through proactive, personalized care. One in three people with diabetes faces the hidden threat of kidney disease. Our flagship solution, NaviDKD®, is an innovative blood test that identifies this risk years in advance, enabling personalized preventive care for better health outcomes. By empowering early action, we aim to significantly reduce the burden of diabetes-related kidney disease on patients and healthcare systems. Discover more at journeybio.life.

For media inquiries: media@journeybio.life